Watch INAB. Know when insiders buy.
One email the day a filing lands. Free.
INAB
IN8BIO, INC.
1.07
+0.06 +5.94%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$18.7MNET CASH —52W 0.96 – 2.59SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.8M | −$4.8M | — | -0.25 | −$3.7M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$5.1M | −$5.1M | — | -0.26 | −$4.9M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.9M | −$4.9M | — | -0.26 | −$2.1M | — | — | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$3.9M | −$3.9M | — | -0.85 | −$3.5M | $0 | −$3.5M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$5.1M | −$5.1M | — | -1.24 | −$3.9M | $0 | −$3.9M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$5.5M | −$5.5M | — | -2.16 | −$3.1M | $0 | −$3.1M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.2M | −$6.2M | — | -1.03 | −$4M | — | — | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$7.1M | −$7.1M | — | -4.49 | −$6.1M | $0 | −$6.1M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$8.6M | −$8.6M | — | -5.51 | −$6.1M | $21K | −$6.1M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$8.6M | −$8.6M | — | -0.20 | −$7.9M | $50K | −$8M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$7.6M | −$7.6M | — | -0.21 | −$4.8M | — | — | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$7.2M | −$7.2M | — | -0.23 | −$5.7M | $0 | −$5.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$19.4M | −$19.4M | — | -4.44 | −$12.7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$30.4M | −$30.4M | — | -17.05 | −$24.1M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$30M | −$30M | — | -1.00 | −$23.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$28.5M | −$28.5M | — | -1.36 | −$24.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$14.7M | −$14.7M | — | -1.47 | −$13.5M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$8.6M | −$8.6M | — | -3.02 | −$7.1M | — | — | — | — |
Every number comes from IN8BIO, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.